Published in Cancer Res on July 15, 2007
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A (2007) 3.21
For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer (2010) 2.26
Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol (2011) 2.06
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica (2010) 1.83
Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res (2013) 1.65
Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood (2009) 1.62
Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med (2009) 1.52
The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem (2008) 1.46
Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther (2009) 1.38
Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. Structure (2009) 1.36
High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chem Biol (2011) 1.27
The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci U S A (2010) 1.20
Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem (2009) 1.14
Why target PIM1 for cancer diagnosis and treatment? Future Oncol (2010) 1.12
Rapid determination of multiple linear kinase substrate motifs by mass spectrometry. Chem Biol (2012) 1.01
Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther (2009) 1.00
Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor. PLoS One (2009) 0.99
The design and application of target-focused compound libraries. Comb Chem High Throughput Screen (2011) 0.97
A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Leuk Res (2011) 0.94
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem (2012) 0.90
Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol (2010) 0.90
PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. Br J Cancer (2012) 0.89
Regulation of Skp2 levels by the Pim-1 protein kinase. J Biol Chem (2010) 0.87
Targeting diverse signaling interaction sites allows the rapid generation of bivalent kinase inhibitors. ACS Chem Biol (2011) 0.87
Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor. ACS Med Chem Lett (2011) 0.86
The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets. Oncotarget (2014) 0.84
Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase. J Biol Chem (2010) 0.83
Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion. Mol Cancer (2010) 0.83
Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression. World J Gastroenterol (2014) 0.82
Clinical and therapeutic relevance of PIM1 kinase in gastric cancer. Gastric Cancer (2011) 0.81
Computational prediction and experimental validation of a novel synthesized pan-PIM inhibitor PI003 and its apoptosis-inducing mechanisms in cervical cancer. Oncotarget (2015) 0.80
Pim kinases in hematological malignancies: where are we now and where are we going? J Hematol Oncol (2014) 0.79
Four-component synthesis of 1,2-dihydropyridine derivatives and their evaluation as anticancer agents. Med Chem (2012) 0.79
Effect of single amino acid substitution observed in cancer on Pim-1 kinase thermodynamic stability and structure. PLoS One (2013) 0.79
Flexibility of the P-loop of Pim-1 kinase: observation of a novel conformation induced by interaction with an inhibitor. Acta Crystallogr Sect F Struct Biol Cryst Commun (2012) 0.78
Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members. Biochemistry (2016) 0.77
New agents for AML and MDS. Best Pract Res Clin Haematol (2009) 0.76
Crystal structure of pim1 kinase in complex with a pyrido[4,3-d]pyrimidine derivative suggests a unique binding mode. PLoS One (2013) 0.75
Identification of quinones as novel PIM1 kinase inhibitors. Bioorg Med Chem Lett (2016) 0.75
Fragment-hopping-based discovery of a novel chemical series of proto-oncogene PIM-1 kinase inhibitors. PLoS One (2012) 0.75
Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leuk Lymphoma (2016) 0.75
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Histone recognition and large-scale structural analysis of the human bromodomain family. Cell (2012) 5.15
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
A randomized controlled trial of preoperative intra-aortic balloon pump in coronary patients with poor left ventricular function undergoing coronary artery bypass surgery*. Crit Care Med (2013) 4.10
Protein production and purification. Nat Methods (2008) 3.97
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet (2007) 3.94
Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem (2002) 3.91
Linear motif atlas for phosphorylation-dependent signaling. Sci Signal (2008) 3.77
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
Computational redesign of protein-protein interaction specificity. Nat Struct Mol Biol (2004) 3.66
Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell (2009) 3.51
Small-molecule inhibition of BRDT for male contraception. Cell (2012) 3.50
Crystal structure of the tetrameric Mad1-Mad2 core complex: implications of a 'safety belt' binding mechanism for the spindle checkpoint. EMBO J (2002) 3.42
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A (2007) 3.21
Critical residues for structure and catalysis in short-chain dehydrogenases/reductases. J Biol Chem (2002) 2.95
Stem cells in severe infantile spinal muscular atrophy (SMA1). Neuromuscul Disord (2012) 2.78
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A (2006) 2.73
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med (2011) 2.59
Bromodomains as therapeutic targets. Expert Rev Mol Med (2011) 2.52
Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell (2008) 2.46
Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet (2002) 2.46
The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J (2008) 2.36
Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. J Med Chem (2005) 2.34
Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure (2009) 2.33
The (un)targeted cancer kinome. Nat Chem Biol (2010) 2.33
Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2006) 2.29
Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol (2010) 2.26
Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol (2003) 2.24
Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): a model for sustainable development in pediatric oncology. Pediatr Blood Cancer (2013) 2.23
Structure of the CaMKIIdelta/calmodulin complex reveals the molecular mechanism of CaMKII kinase activation. PLoS Biol (2010) 2.22
Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood (2009) 2.20
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood (2004) 2.19
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 2.18
Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites. EMBO J (2008) 2.12
Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol (2014) 2.07
Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol (2011) 2.06
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood (2006) 2.06
The effects of propofol and ketamine on the cytokine levels of children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol (2013) 1.99
Structure and substrate specificity of the Pim-1 kinase. J Biol Chem (2005) 1.96
Specificity profiling of Pak kinases allows identification of novel phosphorylation sites. J Biol Chem (2007) 1.92
The bromodomain interaction module. FEBS Lett (2012) 1.92
IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood (2013) 1.91
Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol (2009) 1.86
Structure and functional characterization of the atypical human kinase haspin. Proc Natl Acad Sci U S A (2009) 1.85
Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res (2013) 1.84
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica (2010) 1.83
Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood (2003) 1.80
Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem (2012) 1.76
Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol (2009) 1.67
Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood (2007) 1.67
Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem (2012) 1.64
An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell (2012) 1.61
Construction of human activity-based phosphorylation networks. Mol Syst Biol (2013) 1.59
Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Mol Biosyst (2011) 1.58
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol (2013) 1.58
Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci U S A (2006) 1.57
Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem (2012) 1.55
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica (2007) 1.54
Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states. Proc Natl Acad Sci U S A (2013) 1.54
Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci U S A (2002) 1.54
Ruthenium half-sandwich complexes bound to protein kinase Pim-1. Angew Chem Int Ed Engl (2006) 1.54
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood (2007) 1.53
PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res (2013) 1.53
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood (2009) 1.52
Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med (2009) 1.52
Coupling PAF signaling to dynein regulation: structure of LIS1 in complex with PAF-acetylhydrolase. Neuron (2004) 1.51
UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci (2008) 1.51
Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest (2009) 1.49
3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem (2011) 1.48
Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. J Biol Chem (2013) 1.46